Referências

Artigos principais

Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur J Heart Fail. 2016 Aug;18(8):891-975.Texto completo external link opens in a new windowResumo external link opens in a new window

Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239.Texto completo external link opens in a new windowResumo external link opens in a new window

McKee PA, Castelli WP, McNamara PM, et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971 Dec 23;285(26):1441-6.Resumo external link opens in a new window

Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007 Sep;93(9):1137-46.Texto completo external link opens in a new windowResumo external link opens in a new window

National Institute for Health and Care Excellence. Chronic heart failure in adults: diagnosis and management. Sep 2018 [internet publication].Texto completo external link opens in a new window

Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA. 1996 May 22-29;275(20):1557-62.Resumo external link opens in a new window

Vasan RS, Larson MG, Benjamin EJ, et al. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med. 1997 May 8;336(19):1350-5.Resumo external link opens in a new window

Kannel WB, D'Agostino RB, Silbershatz H, et al. Profile for estimating risk of heart failure. Arch Intern Med. 1999 Jun 14;159(11):1197-204.Resumo external link opens in a new window

Carabello BA, Crawford FA Jr. Valvular heart disease. N Engl J Med. 1997 Jul 3;337(1):32-41.Resumo external link opens in a new window

Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004 Feb 12;350(7):655-63.Texto completo external link opens in a new windowResumo external link opens in a new window

Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004 Feb 12;350(7):647-54.Texto completo external link opens in a new windowResumo external link opens in a new window

Lip GY, Shantsila E. Anticoagulation versus placebo for heart failure in sinus rhythm. Cochrane Database Syst Rev. 2014 Mar 28;(3):CD003336.Texto completo external link opens in a new windowResumo external link opens in a new window

Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant. 2016 Jan;35(1):1-23.Resumo external link opens in a new window

Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001 Mar 22;344(12):873-80.Texto completo external link opens in a new windowResumo external link opens in a new window

Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005 Apr 14;352(15):1539-49.Texto completo external link opens in a new windowResumo external link opens in a new window

Landoni G, Biondi-Zoccai G, Greco M, et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med. 2012 Feb;40(2):634-46.Resumo external link opens in a new window

Birks EJ, Tansley PD, Hardy J, et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med. 2006 Nov 2;355(18):1873-84.Texto completo external link opens in a new windowResumo external link opens in a new window

Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006 Mar 21;113(11):1424-33.Texto completo external link opens in a new windowResumo external link opens in a new window

Artigos de referência

1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur J Heart Fail. 2016 Aug;18(8):891-975.Texto completo external link opens in a new windowResumo external link opens in a new window

2. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239.Texto completo external link opens in a new windowResumo external link opens in a new window

3. McKee PA, Castelli WP, McNamara PM, et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971 Dec 23;285(26):1441-6.Resumo external link opens in a new window

4. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007 Sep;93(9):1137-46.Texto completo external link opens in a new windowResumo external link opens in a new window

5. National Institute for Health and Care Excellence. Chronic heart failure in adults: diagnosis and management. Sep 2018 [internet publication].Texto completo external link opens in a new window

6. Krum H, Stewart S. Chronic heart failure: time to recognize this major public health problem. Med J Aust. 2006 Feb 20;184(4):147-8.Resumo external link opens in a new window

7. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017 Apr;3(1):7-11.Texto completo external link opens in a new windowResumo external link opens in a new window

8. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics - 2018 update: a report from the American Heart Association. Circulation. 2018 Mar 20;137(12):e67-492.Texto completo external link opens in a new windowResumo external link opens in a new window

9. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant. 1994 Jul-Aug;13(4):S107-12.Resumo external link opens in a new window

10. O'Connell JB. The economic burden of heart failure. Clin Cardiol. 2000 Mar;23(3 Suppl):III6-10.Resumo external link opens in a new window

11. Koelling TM, Chen RS, Lubwama RN, et al. The expanding national burden of heart failure in the United States: the influence of heart failure in women. Am Heart J. 2004 Jan;147(1):74-8.Resumo external link opens in a new window

12. Remes J, Reunanen A, Aromaa A, et al. Incidence of heart failure in eastern Finland: a population-based surveillance study. Eur Heart J. 1992 May;13(5):588-93.Resumo external link opens in a new window

13. Ho KK, Pinsky JL, Kannel WB, et al. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993 Oct;22(4 Suppl A):6-13A.Resumo external link opens in a new window

14. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998 Nov 24;98(21):2282-9.Resumo external link opens in a new window

15. Chae CU, Pfeffer MA, Glynn RJ, et al. Increased pulse pressure and risk of heart failure in the elderly. JAMA. 1999 Feb 17;281(7):634-9.Resumo external link opens in a new window

16. Chen YT, Vaccarino V, Williams CS, et al. Risk factors for heart failure in the elderly: a prospective community-based study. Am J Med. 1999 Jun;106(6):605-12.Resumo external link opens in a new window

17. Kimmelstiel CD, Konstam MA. Heart failure in women. Cardiology. 1995;86(4):304-9.Resumo external link opens in a new window

18. Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. Am J Cardiol. 1996 May 1;77(11):1017-20.Resumo external link opens in a new window

19. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974 Jul;34(1):29-34.Resumo external link opens in a new window

20. Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001 Jun 5;103(22):2668-73.Resumo external link opens in a new window

21. Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J. 1994 Aug;72(2 Suppl):S3-9.Texto completo external link opens in a new windowResumo external link opens in a new window

22. Schillaci G, Vaudo G, Reboldi G, et al. High-density lipoprotein cholesterol and left ventricular hypertrophy in essential hypertension. J Hypertens. 2001 Dec;19(12):2265-70.Resumo external link opens in a new window

23. Horio T, Miyazato J, Kamide K, et al. Influence of low high-density lipoprotein cholesterol on left ventricular hypertrophy and diastolic function in essential hypertension. Am J Hypertens. 2003 Nov;16(11 Pt 1):938-44.Resumo external link opens in a new window

24. Kjekshus J, Pedersen TR, Olsson AG, et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997 Dec;3(4):249-54.Resumo external link opens in a new window

25. Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2000 May;35(6):1628-37.Texto completo external link opens in a new windowResumo external link opens in a new window

26. He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001 Apr 9;161(7):996-1002.Resumo external link opens in a new window

27. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA. 1996 May 22-29;275(20):1557-62.Resumo external link opens in a new window

28. Haider AW, Larson MG, Franklin SS, et al. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med. 2003 Jan 7;138(1):10-6.Resumo external link opens in a new window

29. Vaccarino V, Holford TR, Krumholz HM. Pulse pressure and risk for myocardial infarction and heart failure in the elderly. J Am Coll Cardiol. 2000 Jul;36(1):130-8.Texto completo external link opens in a new windowResumo external link opens in a new window

30. Vasan RS, Larson MG, Benjamin EJ, et al. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med. 1997 May 8;336(19):1350-5.Resumo external link opens in a new window

31. Karch SB, Billingham ME. The pathology and etiology of cocaine-induced heart disease. Arch Pathol Lab Med. 1988 Mar;112(3):225-30.Resumo external link opens in a new window

32. Goldenberg SP, Zeldis SM. Fatal acute congestive heart failure in a patient with idiopathic hemochromatosis and cocaine use. Chest. 1987 Aug;92(2):374-5.Resumo external link opens in a new window

33. O'Keefe DD, Grantham RN, Beierholm EA, et al. Cocaine and the contractile response to catecholamines in right ventricular failure. Am J Physiol. 1977 Sep;233(3):H399-403.Resumo external link opens in a new window

34. Wilhelmsen L, Rosengren A, Eriksson H, et al. Heart failure in the general population of men - morbidity, risk factors and prognosis. J Intern Med. 2001 Mar;249(3):253-61.Texto completo external link opens in a new windowResumo external link opens in a new window

35. Facchini FS, Hollenbeck CB, Jeppesen J, et al. Insulin resistance and cigarette smoking. Lancet. 1992 May 9;339(8802):1128-30.Resumo external link opens in a new window

36. Urbano-Marquez A, Estruch R, Navarro-Lopez F, et al. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med. 1989 Feb 16;320(7):409-15.Resumo external link opens in a new window

37. Rubin E, Urbano-Marquez A. Alcoholic cardiomyopathy. Alcohol Clin Exp Res. 1994 Feb;18(1):111-4.Resumo external link opens in a new window

38. Walsh CR, Larson MG, Evans JC, et al. Alcohol consumption and risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med. 2002 Feb 5;136(3):181-91.Resumo external link opens in a new window

39. Abramson JL, Williams SA, Krumholz HM, et al. Moderate alcohol consumption and risk of heart failure among older persons. JAMA. 2001 Apr 18;285(15):1971-7.Resumo external link opens in a new window

40. He J, Ogden LG, Bazzano LA, et al. Dietary sodium intake and incidence of congestive heart failure in overweight US men and women: first National Health and Nutrition Examination Survey epidemiologic follow-up study. Arch Intern Med. 2002 Jul 22;162(14):1619-24.Resumo external link opens in a new window

41. Lee BH, Goodenday LS, Muswick GJ, et al. Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol. 1987 Jan;9(1):184-8.Texto completo external link opens in a new windowResumo external link opens in a new window

42. Nousiainen T, Vanninen E, Jantunen E, et al. Concomitant impairment of left ventricular systolic and diastolic function during doxorubicin therapy: a prospective radionuclide ventriculographic and echocardiographic study. Leuk Lymphoma. 2002 Sep;43(9):1807-11.Resumo external link opens in a new window

43. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003 Jun 1;97(11):2869-79.Texto completo external link opens in a new windowResumo external link opens in a new window

44. Gottlieb SL, Edmiston WA J., Haywood LJ. Late, late doxorubicin cardiotoxicity. Chest. 1980 Dec;78(6):880-2.Resumo external link opens in a new window

45. Kannel WB, Levy D, Cupples LA. Left ventricular hypertrophy and risk of cardiac failure: insights from the Framingham Study. J Cardiovasc Pharmacol. 1987;10 (Suppl 6):S135-40.Resumo external link opens in a new window

46. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002 Aug 1;347(5):305-13.Texto completo external link opens in a new windowResumo external link opens in a new window

47. Fried LF, Shlipak MG, Crump C, et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol. 2003 Apr 16;41(8):1364-72.Texto completo external link opens in a new windowResumo external link opens in a new window

48. Dries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000 Mar 1;35(3):681-9.Texto completo external link opens in a new windowResumo external link opens in a new window

49. Kannel WB, D'Agostino RB, Silbershatz H, et al. Profile for estimating risk of heart failure. Arch Intern Med. 1999 Jun 14;159(11):1197-204.Resumo external link opens in a new window

50. Carabello BA, Crawford FA Jr. Valvular heart disease. N Engl J Med. 1997 Jul 3;337(1):32-41.Resumo external link opens in a new window

51. Chaudhary BA, Ferguson DS, Speir WA, Jr. Pulmonary edema as a presenting feature of sleep apnea syndrome. Chest. 1982 Jul;82(1):122-4.Resumo external link opens in a new window

52. Fletcher EC, Proctor M, Yu J, et al. Pulmonary edema develops after recurrent obstructive apneas. Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1688-96.Resumo external link opens in a new window

53. Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med. 2001 Jan;163(1):19-25.Resumo external link opens in a new window

54. Abramson J, Berger A, Krumholz HM, et al. Depression and risk of heart failure among older persons with isolated systolic hypertension. Arch Intern Med. 2001 Jul 23;161(14):1725-30.Resumo external link opens in a new window

55. Jiang W, Alexander J, Christopher E, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med. 2001 Aug 13-27;161(15):1849-56.Resumo external link opens in a new window

56. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001 Jul 25;286(4):421-6.Resumo external link opens in a new window

57. Vasan RS, Beiser A, D'Agostino RB, et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA. 2003 Mar 12;289(10):1251-7.Resumo external link opens in a new window

58. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol. 1998 Mar;274(3 Pt 2):R577-95.Resumo external link opens in a new window

59. Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003 Mar 25;107(11):1486-91.Resumo external link opens in a new window

60. Welch S, Plank D, Witt S, et al. Cardiac-specific IGF-1 expression attenuates dilated cardiomyopathy in tropomodulin-overexpressing transgenic mice. Circ Res. 2002 Apr 5;90(6):641-8.Resumo external link opens in a new window

61. Wang L, Ma W, Markovich R, et al. Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ Res. 1998 Sep 7;83(5):516-22.Resumo external link opens in a new window

62. Vecchione C, Colella S, Fratta L, et al. Impaired insulin-like growth factor I vasorelaxant effects in hypertension. Hypertension. 2001 Jun;37(6):1480-5.Resumo external link opens in a new window

63. Vasan RS, Sullivan LM, D'Agostino RB, et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann Intern Med. 2003 Oct 21;139(8):642-8.Resumo external link opens in a new window

64. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004 Feb 12;350(7):655-63.Texto completo external link opens in a new windowResumo external link opens in a new window

65. Wang TJ, Evans JC, Benjamin EJ, et al. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003 Aug 26;108(8):977-82.Resumo external link opens in a new window

66. Aurigemma GP, Gottdiener JS, Shemanski L, et al. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol. 2001 Mar 15;37(4):1042-8.Texto completo external link opens in a new windowResumo external link opens in a new window

67. Small KM, Wagoner LE, Levin AM, et al. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med. 2002 Oct 10;347(15):1135-42.Texto completo external link opens in a new windowResumo external link opens in a new window

68. Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013 Apr;165(4):575-82.Texto completo external link opens in a new windowResumo external link opens in a new window

69. Jankowska EA, von Haehling S, Anker SD, et al. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J. 2013 Mar;34(11):816-29.Texto completo external link opens in a new windowResumo external link opens in a new window

70. Maeder MT, Khammy O, dos Remedios C, et al. Myocardial and systemic iron depletion in heart failure implications for anemia accompanying heart failure. J Am Coll Cardiol. 2011 Jul 26;58(5):474-80.Texto completo external link opens in a new windowResumo external link opens in a new window

71. Verdecchia P, Angeli F, Cavallini C, et al. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. Eur Heart J. 2009 Mar;30(6):679-88.Texto completo external link opens in a new windowResumo external link opens in a new window

72. Strandberg TE, Holme I, Faergeman O, et al. Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction. Am J Cardiol. 2009 May 15;103(10):1381-5.Resumo external link opens in a new window

73. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017 Aug 8;136(6):e137-61.Texto completo external link opens in a new windowResumo external link opens in a new window

74. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000 Apr 1;355(9210):1126-30.Resumo external link opens in a new window

75. Tschope C, Kasner M, Westermann D, et al. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J. 2005 Nov;26(21):2277-84.Texto completo external link opens in a new windowResumo external link opens in a new window

76. Tschope C, Kasner M, Westermann D, et al. Elevated NT-ProBNP levels in patients with increased left ventricular filling pressure during exercise despite preserved systolic function. J Card Fail. 2005 Jun;11(5 Suppl):S28-33.Resumo external link opens in a new window

77. Maisel A. The coming of age of natriuretic peptides: the emperor does have clothes! J Am Coll Cardiol. 2006 Jan 3;47(1):61-4.Texto completo external link opens in a new windowResumo external link opens in a new window

78. Maisel A, Mehra MR. Understanding B-type natriuretic peptide and its role in diagnosing and monitoring congestive heart failure. Clin Cornerstone. 2005;7 (Suppl 1):S7-17.Resumo external link opens in a new window

79. Maisel AS, Clopton P, Krishnaswamy P, et al. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. Am Heart J. 2004 Jun;147(6):1078-84.Resumo external link opens in a new window

80. Mueller C, Laule-Kilian K, Schindler C, et al. Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med. 2006 May 22;166(10):1081-7.Resumo external link opens in a new window

81. Mueller C, Laule-Kilian K, Scholer A, et al. Use of B-type natriuretic peptide for the management of women with dyspnea. Am J Cardiol. 2004 Dec 15;94(12):1510-4.Resumo external link opens in a new window

82. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004 Feb 12;350(7):647-54.Texto completo external link opens in a new windowResumo external link opens in a new window

83. Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol. 2004 May 5;43(9):1590-5.Texto completo external link opens in a new windowResumo external link opens in a new window

84. Wang TJ, Larson MG, Keyes MJ, et al. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation. 2007 Mar 20;115(11):1345-53.Resumo external link opens in a new window

85. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004 Feb 10;109(5):594-600.Resumo external link opens in a new window

86. Asferg C, Usinger L, Kristensen TS, et al. Accuracy of multi-slice computed tomography for measurement of left ventricular ejection fraction compared with cardiac magnetic resonance imaging and two-dimensional transthoracic echocardiography: a systematic review and meta-analysis. Eur J Radiol. 2012 May;81(5):e757-62.Resumo external link opens in a new window

87. Quinn B, Doyle B, McInerney J. Postnatal pre-cordial pain. Pulmonary embolism or peripartum cardiomyopathy. Emerg Med J. 2004 Nov;21(6):746-7.Texto completo external link opens in a new windowResumo external link opens in a new window

88. Chop WM Jr. Extending the New York Heart Association classification system. JAMA. 1985 Jul 26;254(4):505.Resumo external link opens in a new window

89. Nakamura M, Tanaka F, Sato K, et al. B-type natriuretic peptide testing for structural heart disease screening: a general population-based study. J Card Fail. 2005 Dec;11(9):705-12.Resumo external link opens in a new window

90. Valle R, Aspromonte N, Barro S, et al. The NT-proBNP assay identifies very elderly nursing home residents suffering from pre-clinical heart failure. Eur J Heart Fail. 2005 Jun;7(4):542-51.Texto completo external link opens in a new windowResumo external link opens in a new window

91. Flynn KE, Piña IL, Whellan DJ, et al. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009 Apr 8;301(14):1451-9.Texto completo external link opens in a new windowResumo external link opens in a new window

92. O'Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009 Apr 8;301(14):1439-50.Texto completo external link opens in a new windowResumo external link opens in a new window

93. Smart N. Exercise training for heart failure patients with and without systolic dysfunction: an evidence-based analysis of how patients benefit. Cardiol Res Pract. 2010 Sep 30;2011:837238.Texto completo external link opens in a new windowResumo external link opens in a new window

94. Al-Mohammad A, Mant J, Laramee P, et al; Chronic Heart Failure Guideline Development Group. Diagnosis and management of adults with chronic heart failure: summary of updated NICE guidance. BMJ. 2010 Aug 25;341:c4130.Resumo external link opens in a new window

95. McAlister FA, Wiebe N, Ezekowitz JA, et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009 Jun 2;150(11):784-94.Resumo external link opens in a new window

96. Flannery G, Gehrig-Mills R, Billah B, et al. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol. 2008 Mar 15;101(6):865-9.Resumo external link opens in a new window

97. Fauchier L, Pierre B, de Labriolle A, et al. Comparison of the beneficial effect of beta-blockers on mortality in patients with ischaemic or non-ischaemic systolic heart failure: a meta-analysis of randomised controlled trials. Eur J Heart Fail. 2007 Nov;9(11):1136-9.Texto completo external link opens in a new windowResumo external link opens in a new window

98. Nasr IA, Bouzamondo A, Hulot JS, et al. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J. 2007 Feb;28(4):457-62.Texto completo external link opens in a new windowResumo external link opens in a new window

99. Kotecha D, Flather MD, Altman DG, et al. Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. J Am Coll Cardiol. 2017 Jun 20;69(24):2885-96.Texto completo external link opens in a new windowResumo external link opens in a new window

100. Cadrin-Tourigny J, Shohoudi A, Roy D, et al. Decreased mortality with beta-blockers in patients with heart failure and coexisting atrial fibrillation: an AF-CHF substudy. JACC Heart Fail. 2017 Feb;5(2):99-106.Texto completo external link opens in a new windowResumo external link opens in a new window

101. Heran BS, Musini VM, Bassett K, et al. Angiotensin receptor blockers for heart failure. Cochrane Database Syst Rev. 2012 Apr 18;(4):CD003040.Texto completo external link opens in a new windowResumo external link opens in a new window

102. Lee VC, Rhew DC, Dylan M, et al. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med. 2004 Nov 2;141(9):693-704. [Erratum in: Ann Intern Med. 2005 Mar 1;42(5):391.]Resumo external link opens in a new window

103. Wong M, Staszewsky L, Latini R, et al. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data. J Am Coll Cardiol. 2004 Jun 2;43(11):2022-7.Texto completo external link opens in a new windowResumo external link opens in a new window

104. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001 Dec 6;345(23):1667-75.Texto completo external link opens in a new windowResumo external link opens in a new window

105. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003 Sep 6;362(9386):767-71.Resumo external link opens in a new window

106. Weir RA, McMurray JJ, Puu M, et al. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Eur J Heart Fail. 2008 Feb;10(2):157-63.Texto completo external link opens in a new windowResumo external link opens in a new window

107. Sakata Y, Shiba N, Takahashi J, et al. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Eur Heart J. 2015 Apr 14;36(15):915-23.Texto completo external link opens in a new windowResumo external link opens in a new window

108. European Medicines Agency. PRAC recommends against combined use of medicines affecting the renin-angiotensin (RAS) system. Apr 2014 [internet publication].Texto completo external link opens in a new window

109. McMurray JJ, Krum H, Abraham WT, et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N Engl J Med. 2016 Apr 21;374(16):1521-32.Texto completo external link opens in a new windowResumo external link opens in a new window

110. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371(11):993-1004.Texto completo external link opens in a new windowResumo external link opens in a new window

111. Chandra A, Lewis EF, Claggett BL, et al. Effects of sacubitril/valsartan on physical and social activity limitations in patients with heart failure: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiol. 2018 Jun 1;3(6):498-505.Resumo external link opens in a new window

112. Desai AS, McMurray JJ, Packer M, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015 Aug 7;36(30):1990-7.Texto completo external link opens in a new windowResumo external link opens in a new window

113. Carson P, Ziesche S, Johnson G, et al; Vasodilator-Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail. 1999 Sep;5(3):178-87.Resumo external link opens in a new window

114. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004 Nov 11;351(20):2049-57.Texto completo external link opens in a new windowResumo external link opens in a new window

115. Lip GY, Shantsila E. Anticoagulation versus placebo for heart failure in sinus rhythm. Cochrane Database Syst Rev. 2014 Mar 28;(3):CD003336.Texto completo external link opens in a new windowResumo external link opens in a new window

116. Homma S, Thompson JL, Pullicino PM, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012 May 17;366(20):1859-69.Texto completo external link opens in a new windowResumo external link opens in a new window

117. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008 Jun 19;358(25):2667-77.Texto completo external link opens in a new windowResumo external link opens in a new window

118. Gheorghiade M, Patel K, Filippatos G, et al. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail. 2013 May;15(5):551-9.Texto completo external link opens in a new windowResumo external link opens in a new window

119. Vamos M, Erath JW, Hohnloser SH, et al. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J. 2015 Jul 21;36(28):1831-8.Texto completo external link opens in a new windowResumo external link opens in a new window

120. Ziff OJ, Lane DA, Samra M, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015 Aug 30;351:h4451.Texto completo external link opens in a new windowResumo external link opens in a new window

121. Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014 Sep 18;371(12):1091-9.Texto completo external link opens in a new windowResumo external link opens in a new window

122. Pitt B, Bakris G, Ruilope LM, et al. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2008 Oct 14;118(16):1643-50.Resumo external link opens in a new window

123. National Institute for Health and Care Excellence. Ivabradine for treating chronic heart failure. Nov 2012 [internet publication].Texto completo external link opens in a new window

124. McKelvie RS, Moe GW, Ezekowitz JA, et al. The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. Can J Cardiol. 2013 Feb;29(2):168-81.Resumo external link opens in a new window

125. Mudge GH, Goldstein S, Addonizio LJ, et al. 24th Bethesda conference: Cardiac transplantation. Task Force 3: Recipient guidelines/prioritization. J Am Coll Cardiol. 1993 Jul;22(1):21-31.Texto completo external link opens in a new windowResumo external link opens in a new window

126. Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant. 2016 Jan;35(1):1-23.Resumo external link opens in a new window

127. Mehra MR, Kobashigawa JA. Advances in heart and lung transplantation 2004: report from the 24th International Society for Heart and Lung Transplantation Annual Meeting, San Francisco, 21-24 April 2004. J Heart Lung Transplant. 2004 Aug;23(8):925-30.Resumo external link opens in a new window

128. Miller LW. Listing criteria for cardiac transplantation: results of an American Society of Transplant Physicians-National Institutes of Health conference. Transplantation. 1998 Oct 15;66(7):947-51.Resumo external link opens in a new window

129. Bardy GH, Lee KL, Mark DB, Poole JE, et al; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005 Jan 20;352(3):225-37.Texto completo external link opens in a new windowResumo external link opens in a new window

130. Jarcho JA. Biventricular pacing. N Engl J Med. 2006 Jul 20;355(3):288-94.Resumo external link opens in a new window

131. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004 May 20;350(21):2140-50.Texto completo external link opens in a new windowResumo external link opens in a new window

132. De Marco T, Wolfel E, Feldman AM, et al. Impact of cardiac resynchronization therapy on exercise performance, functional capacity, and quality of life in systolic heart failure with QRS prolongation: COMPANION trial sub-study. J Card Fail. 2008 Feb;14(1):9-18.Resumo external link opens in a new window

133. Linde C, Abraham WT, Gold MR, et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008 Dec 2;52(23):1834-43.Texto completo external link opens in a new windowResumo external link opens in a new window

134. Mark DB, Anstrom KJ, Sun JL, et al. Quality of life with defibrillator therapy or amiodarone in heart failure. N Engl J Med. 2008 Sep 4;359(10):999-1008.Texto completo external link opens in a new windowResumo external link opens in a new window

135. Bertoldi EG, Polanczyk CA, Cunha V, et al. Mortality reduction of cardiac resynchronization and implantable cardioverter-defibrillator therapy in heart failure: an updated meta-analysis. Does recent evidence change the standard of care? J Card Fail. 2011 Oct;17(10):860-6.Resumo external link opens in a new window

136. Cleland JG, Freemantle N, Erdmann E, et al. Long-term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization-Heart Failure (CARE-HF) trial. Eur J Heart Fail. 2012 Jun;14(6):628-34.Texto completo external link opens in a new windowResumo external link opens in a new window

137. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001 Mar 22;344(12):873-80.Texto completo external link opens in a new windowResumo external link opens in a new window

138. Nelson GS, Berger RD, Fetics BJ, et al. Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block. Circulation. 2000 Dec 19;102(25):3053-9.Resumo external link opens in a new window

139. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002 Jun 13;346(24):1845-53.Texto completo external link opens in a new windowResumo external link opens in a new window

140. Cleland JG, Daubert JC, Erdmann E, et al. The CARE-HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end-points. Eur J Heart Fail. 2001 Aug;3(4):481-9.Texto completo external link opens in a new windowResumo external link opens in a new window

141. Cleland JG, Daubert JC, Erdmann E, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J. 2006 Aug;27(16):1928-32.Texto completo external link opens in a new windowResumo external link opens in a new window

142. Calvert MJ, Freemantle N, Cleland JG. The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study. Eur J Heart Fail. 2005 Mar 2;7(2):243-51.Texto completo external link opens in a new windowResumo external link opens in a new window

143. Calvert MJ, Freemantle N, Yao G, et al. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. Eur Heart J. 2005 Dec;26(24):2681-8.Texto completo external link opens in a new windowResumo external link opens in a new window

144. Ellenbogen KA, Wood MA, Klein HU. Why should we care about CARE-HF? J Am Coll Cardiol. 2005 Dec 20;46(12):2199-203.Texto completo external link opens in a new windowResumo external link opens in a new window

145. Hoppe UC, Casares JM, Eiskjaer H, et al. Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation. 2006 Jul 4;114(1):18-25.Resumo external link opens in a new window

146. Cleland JG, Daubert JC, Erdmann E, et al. Baseline characteristics of patients recruited into the CARE-HF study. Eur J Heart Fail. 2005 Mar 2;7(2):205-14.Texto completo external link opens in a new windowResumo external link opens in a new window

147. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005 Apr 14;352(15):1539-49.Texto completo external link opens in a new windowResumo external link opens in a new window

148. Cleland JG, Calvert MJ, Verboven Y, et al. Effects of cardiac resynchronization therapy on long-term quality of life: an analysis from the CArdiac Resynchronisation-Heart Failure (CARE-HF) study. Am Heart J. 2009 Mar;157(3):457-66.Resumo external link opens in a new window

149. Ghio S, Freemantle N, Scelsi L, et al. Long-term left ventricular reverse remodelling with cardiac resynchronization therapy: results from the CARE-HF trial. Eur J Heart Fail. 2009 May;11(5):480-8.Texto completo external link opens in a new windowResumo external link opens in a new window

150. Cleland J, Freemantle N, Ghio S, et al. Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial. J Am Coll Cardiol. 2008 Aug 5;52(6):438-45.Texto completo external link opens in a new windowResumo external link opens in a new window

151. Lindenfeld J, Feldman AM, Saxon L, et al. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation. 2007 Jan 16;115(2):204-12.Resumo external link opens in a new window

152. Daubert C, Gold MR, Abraham WT, et al. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction. J Am Coll Cardiol. 2009 Nov 10;54(20):1837-46.Texto completo external link opens in a new windowResumo external link opens in a new window

153. Linde C, Gold MR, Abraham WT, et al. REVERSE study: CRT produces long-term improvements in disease progression in mildly symptomatic heart failure patients. Five-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction study. Paper presented at: European Society of Cardiology Congress 2012. 27 August 2012. Munich, Germany.

154. Peura JL, Colvin-Adams M, Francis GS, et al. Recommendations for the use of mechanical circulatory support: device strategies and patient selection. A scientific statement from the American Heart Association. Circulation. 2012 Nov 27;126(22):2648-67.Texto completo external link opens in a new windowResumo external link opens in a new window

155. Zwisler AD, Soja AM, Rasmussen S, et al. Hospital-based comprehensive cardiac rehabilitation versus usual care among patients with congestive heart failure, ischemic heart disease, or high risk of ischemic heart disease: 12-month results of a randomized clinical trial. Am Heart J. 2008 Jun;155(6):1106-13.Resumo external link opens in a new window

156. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003 Jul 5;362(9377):7-13.Resumo external link opens in a new window

157. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005 Feb;26(3):215-25.Texto completo external link opens in a new windowResumo external link opens in a new window

158. Triposkiadis F, Giamouzis G, Kelepeshis G, et al. Acute hemodynamic effects of moderate doses of nebivolol versus metoprolol in patients with systolic heart failure. Int J Clin Pharmacol Ther. 2007 Feb;45(2):71-7.Resumo external link opens in a new window

159. Richardson A, Bayliss J, Scriven AJ, et al. Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure. Lancet. 1987 Sep 26;2(8561):709-11.Resumo external link opens in a new window

160. Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA. 1988 Jan 22-29;259(4):539-44.Resumo external link opens in a new window

161. Wilson JR, Reichek N, Dunkman WB, et al. Effect of diuresis on the performance of the failing left ventricle in man. Am J Med. 1981 Feb;70(2):234-9.Resumo external link opens in a new window

162. Elkayam U, Johnson JV, Shotan A, et al. Double-blind, placebo-controlled study to evaluate the effect of organic nitrates in patients with chronic heart failure treated with angiotensin-converting enzyme inhibition. Circulation. 1999 May 25;99(20):2652-7.Resumo external link opens in a new window

163. Elkayam U, Karaalp IS, Wani OR, et al. The role of organic nitrates in the treatment of heart failure. Prog Cardiovasc Dis. 1999 Jan-Feb;41(4):255-64.Resumo external link opens in a new window

164. Watanabe H, Kakihana M, Ohtsuka S, et al. Preventive effects of carvedilol on nitrate tolerance - a randomized, double-blind, placebo-controlled comparative study between carvedilol and arotinolol. J Am Coll Cardiol. 1998 Nov;32(5):1201-6.Texto completo external link opens in a new windowResumo external link opens in a new window

165. Watanabe H, Kakihana M, Ohtsuka S, et al. Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure. J Am Coll Cardiol. 1998 Nov;32(5):1194-200.Texto completo external link opens in a new windowResumo external link opens in a new window

166. Bauer JA, Fung HL. Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation. 1991 Jul;84(1):35-9.Resumo external link opens in a new window

167. Gogia H, Mehra A, Parikh S, et al. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol. 1995 Dec;26(7):1575-80.Texto completo external link opens in a new windowResumo external link opens in a new window

168. Fogelman AM, La Mont JT, Finkelstein S, et al. Fallibility of plasma-digoxin in differentiating toxic from non-toxic patients. Lancet. 1971 Oct 2;2(7727):727-9.Resumo external link opens in a new window

169. Ingelfinger JA, Goldman P. The serum digitalis concentration - does it diagnose digitalis toxicity? N Engl J Med. 1976 Apr 15;294(16):867-70.Resumo external link opens in a new window

170. Jelliffe RW, Brooker G. A nomogram for digoxin therapy. Am J Med. 1974 Jul;57(1):63-8.Resumo external link opens in a new window

171. Massie B, Chatterjee K, Werner J, et al. Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure. Am J Cardiol. 1977 Nov;40(5):794-801.Resumo external link opens in a new window

172. Pierpont GL, Cohn JN, Franciosa JA. Combined oral hydralazine-nitrate therapy in left ventricular failure. Hemodynamic equivalency to sodium nitroprusside. Chest. 1978 Jan;73(1):8-13.Resumo external link opens in a new window

173. Landoni G, Biondi-Zoccai G, Greco M, et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med. 2012 Feb;40(2):634-46.Resumo external link opens in a new window

174. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002 Jul 20;360(9328):196-202.Resumo external link opens in a new window

175. Adamopoulos S, Parissis JT, Iliodromitis EK, et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol. 2006 Jul 1;98(1):102-6.Resumo external link opens in a new window

176. Tavazzi L, Maggioni AP, Marchioli R, et al; Gissi-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Oct 4;372(9645):1223-30.Resumo external link opens in a new window

177. Kwak SM, Myung SK, Lee YJ, et al. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med. 2012 May 14;172(9):686-94.Resumo external link opens in a new window

178. Torre-Amione G, Anker SD, Bourge RC, et al. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet. 2008 Jan 19;371(9608):228-36.Resumo external link opens in a new window

179. Tritos NA, Danias PG. Growth hormone therapy in congestive heart failure due to left ventricular systolic dysfunction: a meta-analysis. Endocr Pract. 2008 Jan-Feb;14(1):40-9.Resumo external link opens in a new window

180. Le Corvoisier P, Hittinger L, Chanson P, et al. Cardiac effects of growth hormone treatment in chronic heart failure: a meta-analysis. J Clin Endocrinol Metab. 2007 Jan;92(1):180-5.Resumo external link opens in a new window

181. Zhang L, Lu Y, Jiang H, et al. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol. 2012 Mar 6;59(10):913-22.Texto completo external link opens in a new windowResumo external link opens in a new window

182. Sánchez LA, Guerrero-Beltrán CE, Cordero-Reyes AM, et al. Use of stem cells in heart failure treatment: where we stand and where we are going. Methodist Debakey Cardiovasc J. 2013 Oct-Dec;9(4):195-200.Texto completo external link opens in a new windowResumo external link opens in a new window

183. Fisher SA, Doree C, Mathur A, et al. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst Rev. 2016 Dec 24;(12):CD007888.Texto completo external link opens in a new windowResumo external link opens in a new window

184. Tilemann L, Ishikawa K, Weber T, et al. Gene therapy for heart failure. Circ Res. 2012 Mar 2;110(5):777-93.Texto completo external link opens in a new windowResumo external link opens in a new window

185. Hammond HK, Penny WF, Traverse JH, et al. Intracoronary gene transfer of adenylyl cyclase 6 in patients with heart failure: a randomized clinical trial. JAMA Cardiol. 2016 May 1;1(2):163-71.Texto completo external link opens in a new windowResumo external link opens in a new window

186. Greenberg B, Butler J, Felker GM, et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet. 2016 Mar 19;387(10024):1178-86.Resumo external link opens in a new window

187. Goldstein DJ, Oz MC, Rose EA. Implantable left ventricular assist devices. N Engl J Med. 1998 Nov 19;339(21):1522-33.Resumo external link opens in a new window

188. DeRose JJ, Argenziano M, Sun BC, et al. Implantable left ventricular assist devices: an evolving long-term cardiac replacement therapy. Ann Surg. 1997 Oct;226(4):461-70.Texto completo external link opens in a new windowResumo external link opens in a new window

189. DeRose JJ Jr, Umana JP, Argenziano M, et al. Implantable left ventricular assist devices provide an excellent outpatient bridge to transplantation and recovery. J Am Coll Cardiol. 1997 Dec;30(7):1773-7.Texto completo external link opens in a new windowResumo external link opens in a new window

190. Oz MC, Argenziano M, Catanese KA, et al. Bridge experience with long-term implantable left ventricular assist devices. Are they an alternative to transplantation? Circulation. 1997 Apr 1;95(7):1844-52.Resumo external link opens in a new window

191. Mann DL, Willerson JT. Left ventricular assist devices and the failing heart: a bridge to recovery, a permanent assist device, or a bridge too far? Circulation. 1998 Dec 1;98(22):2367-9.Resumo external link opens in a new window

192. Helman DN, Addonizio LJ, Morales DL, et al. Implantable left ventricular assist devices can successfully bridge adolescent patients to transplant. J Heart Lung Transplant. 2000 Feb;19(2):121-6.Resumo external link opens in a new window

193. Yacoub MH. A novel strategy to maximize the efficacy of left ventricular assist devices as a bridge to recovery. Eur Heart J. 2001 Apr;22(7):534-40.Texto completo external link opens in a new windowResumo external link opens in a new window

194. Stevenson LW, Rose EA. Left ventricular assist devices: bridges to transplantation, recovery, and destination for whom? Circulation. 2003 Dec 23;108(25):3059-63.Resumo external link opens in a new window

195. Vitali E, Lanfranconi M, Bruschi G, et al. Left ventricular assist devices as bridge to heart transplantation: the Niguarda Experience. J Card Surg. 2003 Mar-Apr;18(2):107-13.Resumo external link opens in a new window

196. Topkara VK, Dang NC, Martens TP, et al. Bridging to transplantation with left ventricular assist devices: outcomes in patients aged 60 years and older. J Thorac Cardiovasc Surg. 2005 Sep;130(3):881-2.Texto completo external link opens in a new windowResumo external link opens in a new window

197. Zimpfer D, Zrunek P, Roethy W, et al. Left ventricular assist devices decrease fixed pulmonary hypertension in cardiac transplant candidates. J Thorac Cardiovasc Surg. 2007 Mar;133(3):689-95.Texto completo external link opens in a new windowResumo external link opens in a new window

198. Rose EA, Moskowitz AJ, Packer M, et al. The REMATCH trial: rationale, design, and end points. Ann Thorac Surg. 1999 Mar;67(3):723-30.Resumo external link opens in a new window

199. Goldstein DJ, Beauford RB. Left ventricular assist devices and bleeding: adding insult to injury. Ann Thorac Surg. 2003 Jun;75(6 Suppl):S42-7.Resumo external link opens in a new window

200. Gordon SM, Schmitt SK, Jacobs M, et al. Nosocomial bloodstream infections in patients with implantable left ventricular assist devices. Ann Thorac Surg. 2001 Sep;72(3):725-30.Resumo external link opens in a new window

201. Rothenburger M, Schmid C, Huelksen G, et al. Thrombolytic therapy due to thrombus formation associated with left ventricular assist devices. J Heart Lung Transplant. 2005 Dec;24(12):2305.Resumo external link opens in a new window

202. Helman DN, Maybaum SW, Morales DL, et al. Recurrent remodeling after ventricular assistance: is long-term myocardial recovery attainable? Ann Thorac Surg. 2000 Oct;70(4):1255-8.Resumo external link opens in a new window

203. Birks EJ, Tansley PD, Hardy J, et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med. 2006 Nov 2;355(18):1873-84.Texto completo external link opens in a new windowResumo external link opens in a new window

204. Bourge RC, Abraham WT, Adamson PB, et al. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol. 2008 Mar 18;51(11):1073-9.Texto completo external link opens in a new windowResumo external link opens in a new window

205. Adamson PB, Gold MR, Bennett T, et al. Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of The Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) trial. Congest Heart Fail. 2011 Sep-Oct;17(5):248-54.Texto completo external link opens in a new windowResumo external link opens in a new window

206. Klein P, Bax JJ, Shaw LJ, et al. Early and late outcome of left ventricular reconstruction surgery in ischemic heart disease. Eur J Cardiothorac Surg. 2008 Dec;34(6):1149-57.Texto completo external link opens in a new windowResumo external link opens in a new window

207. Bolling SF, Pagani FD, Deeb GM, et al. Intermediate-term outcome of mitral reconstruction in cardiomyopathy. J Thorac Cardiovasc Surg. 1998 Feb;115(2):381-8.Texto completo external link opens in a new windowResumo external link opens in a new window

208. Wu AH, Aaronson KD, Bolling SF, et al. Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol. 2005 Feb 1;45(3):381-7.Texto completo external link opens in a new windowResumo external link opens in a new window

209. Athanasuleas CL, Stanley AW, Jr., Buckberg GD, et al. Surgical anterior ventricular endocardial restoration (SAVER) in the dilated remodeled ventricle after anterior myocardial infarction: RESTORE group – Reconstructive Endoventricular Surgery, returning Torsion Original Radius Elliptical Shape to the LV. J Am Coll Cardiol. 2001 Apr;37(5):1199-209.Texto completo external link opens in a new windowResumo external link opens in a new window

210. Lund LH, Aaronson KD, Mancini DM. Predicting survival in ambulatory patients with severe heart failure on beta-blocker therapy. Am J Cardiol. 2003 Dec 1;92(11):1350-4.Resumo external link opens in a new window

211. Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation. 1997 Jun 17;95(12):2660-7.Resumo external link opens in a new window

212. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006 Mar 21;113(11):1424-33.Texto completo external link opens in a new windowResumo external link opens in a new window

213. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003 Nov 19;290(19):2581-7.Resumo external link opens in a new window

214. Fonarow GC, Adams KF, Jr., Abraham WT, et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005 Feb 2;293(5):572-80.Resumo external link opens in a new window

215. Brophy JM, Dagenais GR, McSherry F, et al. A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction. Am J Med. 2004 Mar 1;116(5):300-4.Resumo external link opens in a new window

216. Koelling TM, Joseph S, Aaronson KD. Heart failure survival score continues to predict clinical outcomes in patients with heart failure receiving beta-blockers. J Heart Lung Transplant. 2004 Dec;23(12):1414-22.Resumo external link opens in a new window

217. Raphael CE, Whinnett ZI, Davies JE, et al. Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure. Heart. 2009 Jan;95(1):56-62.Resumo external link opens in a new window

218. Gerstein HC, Swedberg K, Carlsson J, et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med. 2008 Aug 11;168(15):1699-704.Resumo external link opens in a new window

219. Castel MA, Magnani S, Mont L, et al. Survival in New York Heart Association class IV heart failure patients treated with cardiac resynchronization therapy compared with patients on optimal pharmacological treatment. Europace. 2010 Aug;12(8):1136-40.Texto completo external link opens in a new windowResumo external link opens in a new window

220. Ammar KA, Jacobsen SJ, Mahoney DW, et al. Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. Circulation. 2007 Mar 27;115(12):1563-70.Resumo external link opens in a new window

221. Philbin EF, Santella RN, Rocco TA Jr. Angiotensin-converting enzyme inhibitor use in older patients with heart failure and renal dysfunction. J Am Geriatr Soc. 1999 Mar;47(3):302-8.Resumo external link opens in a new window

222. Arnold SB, Byrd RC, Meister W, et al. Long-term digitalis therapy improves left ventricular function in heart failure. N Engl J Med. 1980 Dec 18;303(25):1443-8.Resumo external link opens in a new window

223. Turini GA, Waeber B, Brunner HR. The renin-angiotensin system in refractory heart failure: clinical, hemodynamic and hormonal effects of captopril and enalapril. Eur Heart J. 1983 Jan;4 (Suppl A):189-97.Resumo external link opens in a new window

224. Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J. 1999 Aug;138(2 Pt 1):285-90.Resumo external link opens in a new window

225. Alpert MA. Cardiovascular factors influencing survival in dialysis patients. Adv Perit Dial. 1996;12:110-9.Resumo external link opens in a new window

226. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998 Aug 27;339(9):584-90.Texto completo external link opens in a new windowResumo external link opens in a new window

227. Risler T, Schwab A, Kramer B, et al. Comparative pharmacokinetics and pharmacodynamics of loop diuretics in renal failure. Cardiology. 1994;84 (Suppl 2):155-61.Resumo external link opens in a new window

228. Iorio L. Daily hemofiltration in severe heart failure. Int J Artif Organs. 1998 Dec;21(12):778-80.Resumo external link opens in a new window

229. Iorio L, Nacca RG, Simonelli R, et al. Daily hemofiltration in severe heart failure. Miner Electrolyte Metab. 1999 Jan-Apr;25(1-2):39-42.Resumo external link opens in a new window

230. Iorio L, Simonelli R, Nacca RG, et al. Daily hemofiltration in severe heart failure. Kidney Int Suppl. 1997 Jun;59:S62-5.Resumo external link opens in a new window

231. Iorio L, Simonelli R, Nacca RG, et al. The benefits of daily hemofiltration in the management of anuria in patients with severe heart failure (NYHA IV). Int J Artif Organs. 1998 Aug;21(8):457-9.Resumo external link opens in a new window

232. Horwich TB, Fonarow GC, Hamilton MA, et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol. 2002 Jun 5;39(11):1780-6.Texto completo external link opens in a new windowResumo external link opens in a new window

233. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001 Oct;38(4):955-62.Texto completo external link opens in a new windowResumo external link opens in a new window

234. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000 Jun;35(7):1737-44.Resumo external link opens in a new window

235. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001 Jun 1;37(7):1775-80.Texto completo external link opens in a new windowResumo external link opens in a new window

236. Mancini DM, Katz SD, Lang CC, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003 Jan 21;107(2):294-9.Resumo external link opens in a new window

237. Ghali JK, Anand IS, Abraham WT, et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation. 2008 Jan 29;117(4):526-35.Resumo external link opens in a new window

238. Troughton RW, Frampton CM, Brunner-La Rocca HP, et al. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J. 2014 Jun 14;35(23):1559-67.Texto completo external link opens in a new windowResumo external link opens in a new window

239. Felker GM, Anstrom KJ, Adams KF, et al. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2017 Aug 22;318(8):713-20.Texto completo external link opens in a new windowResumo external link opens in a new window

240. Chaudhry SI, Phillips CO, Stewart SS, et al. Telemonitoring for patients with chronic heart failure: a systematic review. J Card Fail. 2007 Feb;13(1):56-62.Resumo external link opens in a new window

241. Clark RA, Inglis SC, McAlister FA, et al. Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis. BMJ. 2007 May 5;334(7600):942.Texto completo external link opens in a new windowResumo external link opens in a new window

242. Inglis SC, Clark RA, McAlister FA, et al. Which components of heart failure programmes are effective? A systematic review and meta-analysis of the outcomes of structured telephone support or telemonitoring as the primary component of chronic heart failure management in 8323 patients: abridged Cochrane review. Eur J Heart Fail. 2011 Sep;13(9):1028-40.Texto completo external link opens in a new windowResumo external link opens in a new window

243. Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011 Feb 19;377(9766):658-66.Resumo external link opens in a new window

244. Inglis SC, Clark RA, Dierckx R, et al. Structured telephone support or non-invasive telemonitoring for patients with heart failure. Cochrane Database Syst Rev. 2015 Oct 31;(10):CD007228.Texto completo external link opens in a new windowResumo external link opens in a new window

245. Ades PA, Keteyian SJ, Balady GJ, et al. Cardiac rehabilitation exercise and self-care for chronic heart failure. JACC Heart Fail. 2013 Dec;1(6):540-7.Texto completo external link opens in a new windowResumo external link opens in a new window

246. Piepoli MF, Conraads V, Corrà U, et al. Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail. 2011 Apr;13(4):347-57.Texto completo external link opens in a new windowResumo external link opens in a new window

O uso deste conteúdo está sujeito aos nossos avisos legais